Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials

BACKGROUND: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined the impact of erlotinib in confirmed EGFR wildtype patients in two placebo-controlled phase III trials: the National Cancer I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Lung Cancer Res
Autors principals: Osarogiagbon, Raymond U., Cappuzzo, Federico, Ciuleanu, Tudor, Leon, Larry, Klughammer, Barbara
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4549481/
https://ncbi.nlm.nih.gov/pubmed/26380188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars